For instance, in bevacizumab-resistant tumors, brivanib (dual FGF/VEGF inhibitor) increases the overall survival (OS) in a mouse model of pancreatic neuroendocrine tumor, dovitinib (VEGFR, FGFR and PDGR inhibitor) delays tumor growth, and S49076 (MET, AXL, and FGFR kinase inhibitor) induces tumor growth arrest [47,49,50]. Here, MET is linked to pancreatic neuroendocrine tumor.